Skip to main content
. Author manuscript; available in PMC: 2011 Dec 1.
Published in final edited form as: Gynecol Oncol. 2010 Sep 25;119(3):484–490. doi: 10.1016/j.ygyno.2010.08.016

Figure 2.

Figure 2

Idealized model for tumor progression for the average patient with low CD31-MVD tumor and high CD31-MVD tumor on anti-VEGF therapy and after discontinuation of anti-VEGF therapy. Both representative cases began with the same degree of tumor burden that was noted on radiographic imaging and was monitored during the time of the study.